C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT
Conditions
Multiple Myeloma
Conditions: official terms
Multiple Myeloma - Neoplasms, Plasma Cell
Conditions: Keywords
C11-acetate PET/CT, Multiple myeloma, Pretreatment staging, Response assessment
Study Type
Interventional
Study Phase
N/A
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic
Intervention
Name: ACT PET/CT
Type: Other
Overall Status
Recruiting
Summary
Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM). This study aimed to prospectively assess the clinical utility of ACT PET/CT in MM as compared to the commonly used F18-fluorodeoxyglucose(FDG).
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 20 Years
Gender: Both
Criteria: Inclusion Criteria:

- at least 20 years of age

- previously untreated

- complete pre-treatment clinical staging including bone marrow examination

- written informed consent to participate in the study

Exclusion Criteria:

- concurrent active malignant tumor(s)

- pregnant or breast feeding women

- non-compliant to PET/CT or to MRI

- marked renal impairment (contraindicated for contrast-enhanced MRI)
Location
Chang Gung Memorial Hostpial
Gueishan, Taoyuan county, Taiwan
Status: Recruiting
Contact: Chieh Lin, MD, PhD - +886 3 3281200 - sophieclin@gmail.com
Start Date
May 2011
Completion Date
December 2015
Sponsors
Chang Gung Memorial Hospital
Source
Chang Gung Memorial Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page